NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is making tumor cells more visible to the immune system by triggering neoantigen production

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.

Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune system regards as non-self -- including T cell therapies and cancer vaccines that either target or deliver the newly formed antigens.

NeoPhore Ltd. wants to take a different tack by creating the neoantigens in the patient to make the tumors more visible to the immune

Read the full 788 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE